» 
Meet our new CFO!
Copy URL
https://www.pharmnovo.com/post/meet-our-new-cfo

Meet our new CFO!

September 9, 2023

PharmNovo, currently at the clinical stage of pioneering a novel solution for neuropathic pain treatment, is pleased to announce the appointment of Alexander Dahlquist as the new CFO.

Alexander assumed the role of CFO in August and will leverage his extensive cross-industry experience to lead the company's financial functions. With a comprehensive background as a CFO, including his previous role at Coegin Pharma, and recent consultancy for small to medium-sized businesses, his insights will be integral in supporting our mission to develop safe and effective treatments for neuropathic pain. Alexander Dahlquist will play a significant role in supporting the company's journey ahead.

Author:
Copy URL
https://www.pharmnovo.com/post/meet-our-new-cfo

Meet our new CFO!

September 9, 2023

PharmNovo, currently at the clinical stage of pioneering a novel solution for neuropathic pain treatment, is pleased to announce the appointment of Alexander Dahlquist as the new CFO.

Alexander assumed the role of CFO in August and will leverage his extensive cross-industry experience to lead the company's financial functions. With a comprehensive background as a CFO, including his previous role at Coegin Pharma, and recent consultancy for small to medium-sized businesses, his insights will be integral in supporting our mission to develop safe and effective treatments for neuropathic pain. Alexander Dahlquist will play a significant role in supporting the company's journey ahead.

Author:

Latest news

View all
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more